Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025




Number of Shares and Voting Rights of Innate Pharma as of September 1, 2025

MARSEILLE, France–(BUSINESS WIRE)–#ANKET–Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of September 1, 2025:

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502, a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “intend,” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company’s actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

Contacts

For additional information, please contact:

Innate Pharma
Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations
investors@innate-pharma.fr

Medias
communication@innate-pharma.com

Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong




Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

SHANGHAI & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the Hong Kong Department of Health has approved TIVDAK (tisotumab vedotin-tftv) in Hong Kong for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

“Today’s approval of TIVDAK marks an important milestone for Zai Lab, further strengthening our Women’s franchise in Greater China,” said Andrew Zhu, Chief Commercial Officer, Greater China, Zai Lab. “Treatment options for patients with recurrent or metastatic cervical cancer after initial therapy are limited. TIVDAK, the first antibody-drug conjugate (ADC) therapy in cervical cancer, delivers a clinically meaningful survival benefit to patients. With our established commercial infrastructure for ZEJULA in Hong Kong, we are uniquely positioned to ensure TIVDAK reaches patients without delay.”

TIVDAK is currently under regulatory review for its Biologics License Application by China’s National Medical Products Administration (NMPA), which was accepted in March 2025.

About TIVDAK^® (tisotumab vedotin-tftv)

TIVDAK^® (tisotumab vedotin) is an ADC composed of Genmab’s human monoclonal antibody directed to tissue factor (TF) and Pfizer’s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E (MMAE) to the antibody. Nonclinical data suggest that the anticancer activity of tisotumab vedotin is due to the binding of the ADC to TF-expressing cancer cells, followed by internalization of the ADC-TF complex, and release of MMAE via proteolytic cleavage. MMAE disrupts the microtubule network of actively dividing cells, leading to cell cycle arrest and apoptotic cell death. In vitro, tisotumab vedotin also mediates antibody-dependent cellular phagocytosis and antibody-dependent cellular cytotoxicity.

TIVDAK received full approval from U.S. Food and Drug Administration (FDA) in April 2024 for adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy.

Zai Lab has an exclusive license from Seagen Inc., acquired by Pfizer, to develop and commercialize TIVDAK in Greater China (mainland China, Hong Kong, Macau, and Taiwan, collectively).

About Zai Lab

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. Our goal is to leverage our competencies and resources to positively impact human health.

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at https://x.com/ZaiLab_Global.

Zai Lab Forward-Looking Statements

This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements relating to our prospects and plans for developing and commercializing TIVDAK in Hong Kong, the potential benefits of TIVDAK, and the potential treatment of cervical cancer. These forward-looking statements may contain words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business decisions, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission. We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Our SEC filings can be found on our website at www.zailaboratory.com and the SEC’s website at www.sec.gov.

Contacts

For more information, please contact:

Investor Relations:
Christine Chiou / Lina Zhang

+1 (917) 886-6929 / +86 136 8257 6943

christine.chiou1@zailaboratory.com / lina.zhang@zailaboratory.com

Media:
Shaun Maccoun / Xiaoyu Chen

+1 (857) 270-8854 / +86 185 0015 5011

shaun.maccoun@zailaboratory.com / xiaoyu.chen@zailaboratory.com

Nanoparticle Formulation Market Report 2025, with Profiles of Ascension Sciences, DIANT Pharma, ExonanoRNA, Nanoform, NanoVation Therapeutics, NanoVelos, NTT Biopharma, Organoid-X BioTech, & Vaxinano – ResearchAndMarkets.com




Nanoparticle Formulation Market Report 2025, with Profiles of Ascension Sciences, DIANT Pharma, ExonanoRNA, Nanoform, NanoVation Therapeutics, NanoVelos, NTT Biopharma, Organoid-X BioTech, & Vaxinano – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Nanoparticle Formulation Market Industry Trends and Global Forecasts to 2035, by Type of Nanoparticle, Scale of Operation and Key Geographical Regions” report has been added to ResearchAndMarkets.com’s offering.

The global nanoparticle formulation market is estimated to grow from USD 5.1 billion in 2025, to USD 15.1 billion by 2035, at a CAGR of 9.4% during the forecast period to 2035.

Nanoparticle Formulation Market: Growth and Trends

Having demonstrated a strong therapeutic potential across a myriad of diseases, nanoparticle-based drugs have emerged as a promising treatment alternative within a short span. In fact, given the current ongoing pace of research, experts believe that remarkable innovations in the field of nanoparticles (in terms of improvement in disease diagnosis and treatment specificity) are likely to revolutionize the pharma industry in the coming years. Furthermore, the recent initiatives focused on nanotechnology for the detection and control of vector-borne diseases, dialysis, and molecular imaging, have further fueled the demand for these nanoparticles.

In addition, the nanoparticles can be engineered to achieve optimal delivery and overcome the limitations of biological barriers (systemic, microenvironmental and cellular) in the patient’s body owing to their modifiable properties (such as size, shape, surface properties and charge). However, the complex interplay between nanoparticle properties and biological systems requires careful consideration to ensure the safety and efficacy of these nanoscale materials. Various stakeholders, such as contract research organizations, (CROs), and contract development and manufacturing organizations (CDOs / CDMOs) are likely to play a pivotal role in supporting researchers and drug developers to navigate the complexities associated with its design, development and manufacturing.

By leveraging the multifaceted expertise in the field, contract service providers can help streamline the nanoparticle development process, reduce costs, and accelerate the translation of promising nanoparticles from lab scale to clinical scale. Driven by technological advancements and the rising demand for nanoparticle-based drugs, the nanoparticle formulation services market is anticipated to witness notable growth in the foreseen future.

Nanoparticle Formulation Market: Key Insights

The report delves into the current state of the nanoparticle formulation market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

• Presently, more than 100 nanoparticle formulation technologies are being offered by companies across the globe in order to augment the development and manufacturing of nanoparticle-based drugs.
• Close to 80% of technologies are designed for the formulation of organic nanoparticles; of these, nearly 50% are intended for drug delivery via injectable route, primarily targeting oncological disorders.
• The current service providers landscape has over 80 companies offering a wide range of nanoparticle formulation services at various scales of operation.
• The market landscape features the presence of both well-established players and new entrants with the requisite expertise to develop / manufacture nanoparticle-based drugs for an extensive range of application areas.
• Owing to the rise in demand for nanoparticle-based formulations, service providers are continuously expanding their existing capabilities to enhance their respective service portfolios.
• A steady growth in the partnership activity has been observed in recent years; R&D agreements have been the most prominent type of partnership model adopted by players based in the US.
• More than 1,700 patents related to nanoparticle formulation and development have been filed by / granted to various organizations in order to protect intellectual property.
• The nanoparticle formulation services market is likely to grow at a CAGR of ~9% over the next decade, driven by revenues generated from commercial scale operation.

Nanoparticle Formulation Market: Key Segments

Organic Nanoparticles are Likely to Dominate the Nanoparticle Formulation Market During the Forecast Period

Based on the type of nanoparticle, the market is segmented into organic nanoparticles, inorganic nanoparticles and carbon-based nanoparticles. At present, organic nanoparticles hold the maximum share of the nanoparticle formulation market. This trend is unlikely to change in the near future.

Protein-based Nanoparticles Segment is the Fastest Growing Segment of the Nanoparticle Formulation Market During the Forecast Period

Based on the type of organic nanoparticle, the market is segmented into polymeric nanoparticles, lipid nanoparticles, viral nanoparticles, protein-based nanoparticles, and other organic nanoparticles. It is worth highlighting that, currently, lipid nanoparticles hold a larger share of the nanoparticle formulation market. However, the nanoparticle formulation market for protein-based nanoparticles is likely to grow at a higher CAGR in the coming decade.

Commercial Operations Occupy the Largest Share of the Nanoparticle Formulation Market

Based on scales of operation, the market is segmented into preclinical, clinical and commercial scales. At present, commercial operations capture the maximum share of the nanoparticle formulation market. It is worth highlighting that the nanoparticle formulation market at the clinical scale is likely to grow at a higher CAGR in the near future.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the world. The majority share is expected to be captured by service providers based in North America and Europe. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Nanoparticle Formulation Market, Profiled in the Report

• Ascension Sciences
• DIANT Pharma
• ExonanoRNA
• Nanoform
• NanoVation Therapeutics
• NanoVelos
• NTT Biopharma
• Organoid-X BioTech
• Vaxinano

Nanoparticle Formulation Market: Research Coverage

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the nanoparticle formulation market, focusing on key market segments, including type of nanoparticle formulated, type of organic nanoparticle formulated, scale of operation and key geographical regions.
• Market Landscape 1: A comprehensive evaluation of nanoparticle formulation technologies, considering various parameters, such as type of nanoparticle(s) formulated, type of molecule(s) delivered, therapeutic area(s), compatible dosage form(s) and route(s) of administration. Further, the chapter provides information on various technology developers, along with analysis based on multiple parameters, such as year of establishment, company size, location of headquarters and most active players (in terms of number of technologies developed).
• Market Landscape 2: A comprehensive evaluation of nanoparticle formulation service providers, considering various parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, location of facilities, type of service provider(s), type of nanoparticle(s) formulated, type of service(s) offered, scale of operation and application area(s).
• Technology Competitiveness: A comprehensive competitive analysis of nanoparticle formulation technologies, examining factors, such as developer power, technology strength and technology applicability.
• Company Competitiveness: A comprehensive competitive analysis of nanoparticle formulation service providers, examining factors, such as company strength and service strength.
• Company Profiles: In-depth profiles of key industry players offering technologies and services for nanoparticle formulation across North America, Europe and Asia-Pacific, focusing on company overviews, technology portfolio, service portfolio, recent developments and an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2018, covering technology licensing agreements, research and development agreements, product development agreements, manufacturing agreements, mergers and acquisitions, technology integration agreements and other relevant agreements.
• Patent Analysis: Detailed analysis of various patents filed / granted related to nanoparticle formulation based on publication year, geographical region, CPC symbols, leading players (in terms of number of patents filled / granted) and type of organization. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Nanoparticle Evaluation Framework: An insightful framework evaluating types of nanoparticles based on various parameters, such as number of technologies, nanoparticle efficacy, number of clinical trials evaluating nanoparticle-based drugs, extent of innovation, trends in research activity and current global competition. It also provides a value addition matrix for respective types of nanoparticles currently adopted by stakeholders.
• Case Study: A case study of the recent technology licensing agreements, along with information on deal amounts.

Key Questions Answered in this Report

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What factors are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team

For more information about this report visit https://www.researchandmarkets.com/r/uh9gwr

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Digital Biomarkers Global Markets Report 2025-2030 with Profiles of Leading Players – Actigraph, AliveCor, Altoida, Evidation Health, and IXICO – ResearchAndMarkets.com




Digital Biomarkers Global Markets Report 2025-2030 with Profiles of Leading Players – Actigraph, AliveCor, Altoida, Evidation Health, and IXICO – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Digital Biomarkers: Global Markets” report has been added to ResearchAndMarkets.com’s offering.

The global market for digital biomarkers is estimated to grow from $5 billion in 2025 to $18.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 30.4% from 2025 through 2030.

This report provides an overview of the global market for digital biomarkers and analyzes market trends. It includes global revenue ($ millions) for the base year data of 2024, estimates for 2025 and projections of compound annual growth rates (CAGRs) from 2025 through 2030. The market is segmented based on system components, applications, therapeutic areas, end users and regions. The regions covered in this study include North America, Europe, Asia-Pacific and the Rest of the World (RoW), focusing on major countries in these regions.

The report focuses on the significant driving trends and challenges that affect the market and vendor landscape. It analyzes environmental, social and governance (ESG) developments and discusses emerging technologies related to the market.

The report includes:

• 53 data tables and 54 additional tables
• An overview of the global market for digital biomarkers
• Estimation of the market size and analyses of global market trends, with data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Information regarding major market drivers, opportunities and challenges, industry chain structure, distribution channel and technological advancements that are affecting the overall market
• Evaluation of market potential and revenue forecast for the digital biomarkers market based on system component, application, therapeutic area, end user and region
• Insights into the industry structure, current competitive scenario, R&D activities, growth strategies and ESG trends of the market
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and strategic alliances
• Profiles of the leading companies, including Actigraph LLC., AliveCor Inc., Altoida, Evidation Health Inc., and IXICO Plc.

Company Profiles

• Actigraph LLC.
• Akili Inc.
• Alivecor Inc.
• Altoida
• Embic Corp.
• Empatica Inc.
• Evidation Health Inc.
• Feel Therapeutics
• Huma
• Ixico PLC
• Kinsa Inc.
• Koneksa Health
• Neurotrack Technologies Inc.
• Vivosensmedical GmbH
• Winterlight Labs

Key Attributes:

Key Topics Covered:

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview and Market Definition
• Digital Biomarker Types
• Comparison of Traditional and Digital Biomarkers
• Pestel Analysis
• Political
• Economic
• Social
• Technological
• Environmental
• Legal
• Impact of U.S. Tariff Laws on the Digital Biomarkers Market
• Increase in Product Costs
• Effects on Supply Chain
• Opportunities for Local Production
• Conclusion

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rising Adoption of Mhealth Apps and Wearables
• Growing Application of Digital Biomarkers in Neurodegenerative and Psychiatric Disorders
• Increasing Role of Digital Biomarkers in Clinical Trials
• Corporate Wellness Programs and Incentives
• Market Restraints
• Data Standardization and Interpretation Issues
• Difficulties in Validation of Biomarkers
• Data Privacy and Protection
• Market Opportunities
• Growing Technology Innovations
• Increasing Research Collaborations and Partnerships

Chapter 4 Regulatory Landscape

• Regulatory Scenario
• The U.S.
• Canada
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Developments

• Artificial Intelligence-based Digital Biomarkers
• Enhancement of Digital Biomarkers by AI and ML
• Benefits of AI-Driven Digital Biomarkers

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Market Breakdown by System Component
• Key Takeaways
• Data Collection Tools
• Data Integration Systems
• Market Breakdown by Application
• Key Takeaways
• Diagnostic Digital Biomarkers
• Monitoring Digital Biomarkers
• Predictive Digital Biomarkers
• Other Applications
• Market Breakdown by Therapeutic Area
• Key Takeaways
• Cardiovascular and Metabolic Disorders
• Psychiatric Disorders
• Neurological Disorders
• Musculoskeletal Disorders
• Respiratory Disorders
• Other Therapeutic Areas
• Market Breakdown by End-user
• Key Takeaways
• Pharmaceutical Companies and Research Institutions
• Healthcare Providers
• Patients and Caregivers
• Employers
• Payers
• Geographic Breakdown
• Market Breakdown by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Key Takeaways
• Prominent Digital Biomarkers Companies
• Competitor Types and Their Strategies
• Pharmaceutical Companies
• Large Technology Companies
• Small and Medium-Size Technology Companies
• Strategic Analysis
• Agreements, Collaborations and Partnerships
• New Product Launches
• Acquisitions and Mergers
• Regulatory Approvals

Chapter 8 Sustainability in Digital Biomarkers Market: ESG Perspective

• Introduction
• Sustainability Factors
• Environmental Sustainability
• Social Sustainability
• Economic Sustainability
• Other Factors
• Scaling Sustainable Practices in Healthcare
• Business Practices Implementing Sustainable Solutions
• Conclusion

Chapter 9 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/sz3yzs

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

STAT Inhibitors Pipeline Market Insights Report 2025 | 18 Companies and 22 Pipeline Drugs in Stages Ranging from Clinical to Nonclinical – ResearchAndMarkets.com




STAT Inhibitors Pipeline Market Insights Report 2025 | 18 Companies and 22 Pipeline Drugs in Stages Ranging from Clinical to Nonclinical – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “STAT Inhibitors – Pipeline Insight, 2025” has been added to ResearchAndMarkets.com’s offering.

The “STAT Inhibitors – Pipeline Insight, 2025” report offers exhaustive insights into the emerging landscape of STAT Inhibitors, with over 18 companies and 22 pipeline drugs in stages ranging from clinical to nonclinical. The report delves into the therapeutic assessment categorized by product type, stage, route of administration, and molecular type, while also illustrating inactive pipeline products.

Signal Transducer and Activator of Transcription (STAT) inhibitors are pivotal in targeting aberrant STAT signaling, especially involving STAT3 and STAT5, which are linked to diverse diseases like cancers and inflammatory disorders. These inhibitors aim to disrupt the pathological cell behaviors associated with these conditions. Current research underscores their potential in targeted applications, predominantly in oncology and chronic inflammatory diseases.

STAT proteins, encompassing seven members, function as signal transducers directly influencing gene expression. Each protein plays distinct roles, with STAT1 crucial for antiviral responses, STAT3 extensively involved in oncogenesis, and STAT6 impacting immune regulations. Their structural design, comprising domains like the SH2 domain, facilitates signal transduction and transcriptional regulation. Stat proteins’ therapeutic targeting continues to be significant in oncology, autoimmune disorders, and as potential biomarkers for disease progression and treatment efficacy.

The “STAT Inhibitors – Pipeline Insight, 2025” report presents an in-depth look into the current scenario and growth prospects for these inhibitors. It features a detailed landscape of the STAT Inhibitors pipeline, including disease overviews and treatment guidelines, while thoroughly assessing the commercial and clinical facets of ongoing developments.

The report highlights leading drugs in development, providing insights into their mechanisms, clinical trials, approvals, and technological collaborations. Notably, TTI-101 from Tvardi Therapeutics, in Phase II trials, has shown promise against conditions like liver and breast cancer. Similarly, Kymera Therapeutics’ KT-621, a standout oral STAT6 degrader, is in Phase I trials for Atopic Dermatitis, showcasing superior preclinical efficacy. Vividion’s VVD-850, another STAT3 inhibitor, underpins broad cancer applications, currently in early Phase I trials.

A key component of the report is the therapeutic assessment, segmented by various parameters such as clinical stages including Phase III, II, I, preclinical, and discovery stages. Drugs are further categorized by their route of administration, product types, and molecular forms. Active collaborations, mergers, acquisitions, licensing activities, and narrative on clinical studies anchor the comprehensive view presented.

The report canvasses key players like Tvardi Therapeutics, Kymera Therapeutics, Bayer, and Vividion, among others, who are advancing the frontier of STAT Inhibitor research and development.

In summary, the STAT Inhibitors report encapsulates a robust analysis of the pipeline, therapeutic potential, and identifies current unmet needs in the market. It serves as a crucial guide for stakeholders witnessing the evolving capacities of STAT-targeted therapies across various medical disciplines.

Key Topics Covered:

Introduction

Executive Summary

STAT Inhibitors: Overview

• Introduction
• Structure
• Function
• Mechanism of action
• STAT Inhibitors as therapeutic target

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

STAT Inhibitors – Analytical Perspective

Late Stage Products (Phase III)

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

TTI-101: Tvardi Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

VVD-850: Vividion Therapeutics

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

STAT Inhibitors Key Companies

STAT Inhibitors Key Products

STAT Inhibitors – Unmet Needs

STAT Inhibitors – Market Drivers and Barriers

STAT Inhibitors – Future Perspectives and Conclusion

STAT Inhibitors Analyst Views

STAT Inhibitors Key Companies

• Tvardi Therapeutics
• Kymera Therapeutics, Inc
• Vividion Therapeutics
• Bayer
• Moleculin
• Purple Biotech
• LEO Pharma
• Enanta Pharmaceuticals
• Kaken Pharmaceutical
• Astrazeneca
• Arrakis Therapeutics
• Accendatech
• JW Pharmaceutical
• Recludix

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/psf77e

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical Trials – Promising New Drug Developments – ResearchAndMarkets.com




Non Muscle Invasive Bladder Cancer Pipeline Insight Report 2025 | Phase III Clinical Trials – Promising New Drug Developments – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2025” has been added to ResearchAndMarkets.com’s offering.

The “Non Muscle Invasive Bladder Cancer – Pipeline Insight, 2025” report provides a thorough examination of the pipeline landscape for Non Muscle Invasive Bladder Cancer (NMIBC), engaging with over 20 companies and 22 plus pipeline drugs. This report details both clinical and non-clinical stage products, offering insights into therapeutic assessments by product type, stage, and route of administration. Pipeline inactivity is also highlighted.

Non-muscle invasive bladder cancer remains predominantly confined to the bladder wall’s inner layers, manifesting in stages such as Ta, T1, and carcinoma in situ (CIS). It represents about 70-80% of newly diagnosed cases with a high recurrence rate but lower progression risk. Essential management strategies include TURBT followed by intravesical therapies. Regular cystoscopic surveillance is crucial due to high recurrence probabilities.

Therapeutics in development are pioneering novel treatment prospects. Cretostimogene grenadenorepvec from CG Oncology is an oncolytic immunotherapy in Phase III, focusing on tumor-selective replication and immune response amplification. TAR-210 by Janssen Research & Development offers an innovative drug delivery system targeting FGFR alterations. In Phase II, Tyra Biosciences’ TYRA-300 is assessed as an FGFR3-selective inhibitor. UGN-301, from UroGen Pharma Ltd., is an anti-CTLA-4 monoclonal antibody explored in a Phase I study for its effectiveness in maintaining local drug concentrations with reduced systemic exposure.

A comprehensive therapeutic assessment provided in the report classifies drugs by development stages: Phase III, II, I, Preclinical, and Discovery. Various routes of administration such as oral, intravenous, and intravesical are considered, alongside molecule types like small molecules, monoclonal antibodies, and gene therapies.

The report identifies significant players like CG Oncology and Tyra Biosciences, and delves into their pipeline activities, including collaborations, mergers, and licensing. Novel developments like small, bladder-resident devices or selective inhibitors show promising management avenues for NMIBC, especially for patients resistant to traditional therapies like BCG.

A detailed analysis covers emerging drugs, their clinical trial stages, and innovative pharmacological actions. This report highlights unmet needs, advances in drug types, and key designations granted to emerging therapies, positioning it as an essential resource for stakeholders aiming to navigate NMIBC treatment breakthroughs.

For further exploration and insights into NMIBC’s therapeutic landscape, major players such as CG Oncology, Janssen Research & Development, Tyra Biosciences, UroGen Pharma, and others continue to drive the R&D sphere, adapting strategic measures to improve treatment efficacy and patient outcomes by 2025.

Key Topics Covered:

Introduction

Executive Summary

Non Muscle Invasive Bladder Cancer: Overview

• Introduction
• Causes
• Pathophysiology
• Signs and Symptoms
• Diagnosis
• Treatment

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

Non Muscle Invasive Bladder Cancer – Analytical Perspective

Late Stage Products (Phase III)

• Comparative Analysis

Cretostimogene grenadenorepvec: CG Oncology

• Product Description
• Research and Development
• Product Development Activities

Mid Stage Products (Phase II)

• Comparative Analysis

TYRA-300: Tyra Biosciences, Inc

• Product Description
• Research and Development
• Product Development Activities

Early Stage Products (Phase I)

• Comparative Analysis

UGN-301: UroGen Pharma Ltd.

• Product Description
• Research and Development
• Product Development Activities

Preclinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description
• Research and Development
• Product Development Activities

Inactive Products

• Comparative Analysis

Non Muscle Invasive Bladder Cancer Key Companies

Non Muscle Invasive Bladder Cancer Key Products

Non Muscle Invasive Bladder Cancer – Unmet Needs

Non Muscle Invasive Bladder Cancer – Market Drivers and Barriers

Non Muscle Invasive Bladder Cancer – Future Perspectives and Conclusion

Non Muscle Invasive Bladder Cancer Analyst Views

Non Muscle Invasive Bladder Cancer Key Companies

• CG Oncology
• Janssen Research & Development, LLC
• Tyra Biosciences, Inc
• UroGen Pharma Ltd.
• Prokarium Ltd
• Protara Therapeutics
• ImmVira Pharma Co. Ltd
• Trigone Pharma Ltd.
• Hoffmann-La Roche
• Aura Biosciences
• enGene Holdings Inc.
• Atonco Pharma

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/78gzrj

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Gateway to Growth: Innovation and Opportunity at the 8th CIIE




Gateway to Growth: Innovation and Opportunity at the 8th CIIE

SHANGHAI–(BUSINESS WIRE)–Amid a shifting global economy, the China International Import Expo (CIIE) continues to provide a vital gateway for global enterprises. With preparations for the 8^th CIIE well underway, the expo is set to once again showcase innovation, foster cooperation, and expand access to the Chinese dynamic market.

Leveraging the vital platform for global enterprises to access the Chinese massive market, many exhibitors have grown from participants into investors, while numerous exhibits have been transformed into marketable goods. Novartis, for instance, debuted Radioligand Therapy (RLT) at the 4^th CIIE. Benefiting from CIIE’s spillover effect, it signed strategic pacts with three Chinese partners—GE Healthcare China, Shanghai Pharmaceutical Holding and Chongqing Pharmaceutical Holding—at the 7^th CIIE to speed up RLT’s launch and expansion in China.

At the supply-demand matchmaking event of the 8^th CIIE, companies showcased 22 “CIIE Babies” —products that have successfully entered the market after their debut at previous expos, including two making their first post-launch appearance, underscoring the CIIE’s role in turning exhibits into goods. Medical innovations have also gained ground in China. Novartis built on its RLT debut last year by partnering with GE Healthcare China and others to create an RLT ecosystem. Meanwhile, Boston Scientific saw several products move from expo floor to market after the 7^th CIIE. Johnson & Johnson, expanding its booth to 700 square meters this year, will feature the MONARCH surgical robot and the lung cancer therapy Rukobia^®.

In parallel with the 8^th CIIE, this year’s Hongqiao International Economic Forum (HQF) unveiled its theme “Opening Up for New Opportunities, Collaborating for a Shared Future”. As a premier platform for global economic dialogue, the 8^th HQF will feature more than 20 sessions on Opening-up for Cooperation, Innovation, Development and Sharing. Preparations are in full swing, with active participation from international bodies like UNICEF and UNIDO, alongside government officials and industry leaders. The release of the World Openness Report 2025 will be a spotlight of the 8^th HQF, underscoring its role as a key platform for global dialogue and collaboration.

Don’t miss the chance to be part of this global event. The 8^th CIIE offers unparalleled opportunities for businesses to connect, innovate, and grow. Visit https://www.ciie.org/zbh/en/ for the latest updates and participation details.

Contacts

CUI Yan, cuiyan@sinoexpo.cc

Spasticity Pipeline Market Analysis Report 2025 | Comprehensive Insights on 10+ Companies and 12+ Pipeline Drugs – ResearchAndMarkets.com




Spasticity Pipeline Market Analysis Report 2025 | Comprehensive Insights on 10+ Companies and 12+ Pipeline Drugs – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Spasticity – Pipeline Insight, 2025” clinical trials has been added to ResearchAndMarkets.com’s offering.

This “Spasticity – Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Spasticity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Spasticity pipeline landscape is provided which includes the disease overview and Spasticity treatment guidelines. The assessment part of the report embraces, in depth Spasticity commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Spasticity collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Spasticity: Pipeline Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Spasticity therapeutic drugs key players involved in developing key drugs.

Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Spasticity drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Spasticity R&D. The therapies under development are focused on novel approaches to treat/improve Spasticity.

Spasticity Emerging Drugs Chapters

This segment of the Spasticity report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Spasticity Emerging Drugs

MTR-601: Motric Bio

MTR-601, represents a potential first-in-class antispastic therapy with a unique mechanism of action that directly targets the contractile protein – myosin 2 – in fast-twitch skeletal muscle. As an oral, selective inhibitor, MTR-601 is designed to offer a non-invasive approach for the treatment of cervical dystonia, targeting fast-twitch muscle fibers with the potential to decrease stiffness and potentially improve physical function. MTR-601 on a robust body of preclinical data that demonstrates initial activity in selectively relaxing fast-twitch skeletal muscle subtypes. In a preclinical model, MTR-601 was also shown to improve gait function in spastic cerebral palsy. Currently, the drug is in Phase II stage of its development for the treatment of Spasticity.

IPN10200: Ipsen

IPN10200 is a long-acting botulinum neurotoxin candidate developed by Ipsen for the treatment of upper limb spasticity. Engineered for extended duration of effect, it aims to provide sustained relief from muscle hyperactivity by inhibiting acetylcholine release at neuromuscular junctions. As a targeted neurotoxin therapy, IPN10200 is designed to reduce muscle tone more consistently over time, potentially reducing injection frequency and improving patient convenience. Its development reflects Ipsen’s strategic focus on neuroscience and its commitment to advancing innovative therapeutic options in spasticity management. Currently, the drug is in Phase I/II stage of its development for the treatment of Spasticity.

Spasticity: Therapeutic Assessment

Major Players in Spasticity

There are approx. 10+ key companies which are developing the therapies for Spasticity. The companies which have their Spasticity drug candidates in the most advanced stage, i.e. Phase II include, Motric Bio.

Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of:
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Spasticity Report Insights

• Spasticity Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Spasticity Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

• How many companies are developing Spasticity drugs?
• How many Spasticity drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Spasticity?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Spasticity therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Spasticity and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Motric Bio
• Ipsen
• Saol Therapeutics Inc
• Elpida Therapeutics SPC
• Celgene
• Tris Pharma, Inc.

Key Products

• MTR-601
• IPN10200
• SL-1002
• MELPIDA
• BMS-986368
• TRN-213

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/o72tb7

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Corneal Ulcer Market Research Report 2025-2035 | Overview and Ecosystem, Epidemiology, Key Trends, Impact Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics – ResearchAndMarkets.com




Corneal Ulcer Market Research Report 2025-2035 | Overview and Ecosystem, Epidemiology, Key Trends, Impact Analysis, Regulatory Landscape, Pipeline Analysis, Market Dynamics – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Corneal Ulcer Market – A Global and Regional Analysis: Focus on Drug Class and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

The corneal ulcer treatment market is poised for significant growth, driven by advancements in novel therapies, including regenerative treatments and targeted drug delivery systems. As awareness of corneal ulcers continues to rise, particularly in regions with high rates of contact lens usage and microbial infections, demand for effective treatments is expected to grow.

Additionally, improved healthcare infrastructure, especially in emerging markets, will enhance accessibility to advanced care. The growing focus on personalized medicine, combined with favourable reimbursement policies, will further support market expansion. With continued patient education and the development of innovative, more effective therapies, the corneal ulcer treatment market is well-positioned to address the rising need for specialized and targeted treatment options.

Growth in the corneal ulcer treatment market is supported by the increasing recognition of the condition’s impact on patients’ quality of life, especially due to its potential to lead to blindness if untreated. The market is evolving as healthcare providers and pharmaceutical companies focus on early diagnosis and intervention, offering a broader range of treatment options to improve patient outcomes and reduce recurrence of infections. Key therapeutic categories include topical antibiotics, antivirals, antifungals, corticosteroids, and regenerative therapies such as platelet-rich plasma (PRP) and recombinant human nerve growth factors, which are gaining attention for their potential to accelerate corneal healing and improve recovery rates.

Improved healthcare infrastructure in emerging markets, rising awareness among patients, and enhanced access to treatment are significant contributors to market growth. Furthermore, favourable reimbursement policies in developed regions are enabling greater access to advanced treatments, which further drives market expansion. The ongoing development of more targeted therapies and personalized treatment approaches, especially for patients with chronic or recurrent corneal ulcers, is expected to open new opportunities for market growth.

Advancements in drug delivery technologies, such as sustained-release ocular implants, nanoparticle-based therapies, and innovative eye drops, are playing a crucial role in expanding the therapeutic landscape for corneal ulcers. These innovations are designed to improve drug bioavailability, enhance treatment adherence, and minimize side effects, which are key challenges in the current treatment regimen. Additionally, personalized medicine, which takes into account individual patient profiles and genetic factors, is poised to revolutionize the management of corneal ulcers by offering more precise and effective treatment options.

Despite the promising growth prospects, the corneal ulcer market faces several challenges, including the high cost of advanced treatments, limited availability of specialized ophthalmologists, and inconsistent patient adherence to long-term treatment regimens. Moreover, the complex nature of microbial infections and the emergence of antibiotic-resistant pathogens complicate treatment efforts and may limit the effectiveness of current therapies. Regulatory hurdles and lengthy approval timelines for new treatments may also delay the availability of breakthrough therapies, further impacting market dynamics.

The competitive landscape of the corneal ulcer treatment market is characterized by the active involvement of leading pharmaceutical companies, biotechnology firms, and research institutions. Strategic partnerships, mergers, and acquisitions are common as stakeholders seek to enhance their product portfolios and accelerate research into more effective treatments. Investments in research and development, particularly in regenerative therapies, drug delivery systems, and novel antimicrobial agents, will play a key role in shaping the future of the market, aiming to improve clinical efficacy and provide better patient-centric care.

Looking forward, the global corneal ulcer treatment market is poised to continue its growth, driven by the rising incidence of corneal infections, advancements in treatment modalities, and a growing emphasis on patient education and disease prevention. The integration of digital health technologies, such as mobile apps for tracking treatment progress and remote consultations, is expected to improve treatment adherence and facilitate better disease management. With continued focus on personalized medicine and the development of more innovative therapeutic options, the corneal ulcer market is positioned to enhance patient outcomes and quality of life, providing a brighter future for those affected by this debilitating condition worldwide.

Competitive Landscape

• AbbVie Inc. (Allergan plc)
• Baxter International Inc.
• Bayer AG
• Dr. Reddy’s Laboratories Ltd.
• Eli Lilly and Company
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.

Key Topics Covered:

1. Global Corneal Ulcer Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
• 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
• 1.6.1 Overview
• 1.6.2 Market Drivers
• 1.6.3 Market Restraints
• 1.6.4 Market Opportunities

2. Global Corneal Ulcer Market (by Drug Class), Value ($million), 2023-2035

• 2.1 Antibiotics
• 2.2 Antifungals
• 2.3 Antivirals
• 2.4 Corticosteroids
• 2.5 Others

3. Global Corneal Ulcer Market (by Region), Value ($Million), 2023-2035

• 3.1 North America
• 3.1.1 Market Dynamics
• 3.1.2 Market Sizing and Forecast
• 3.1.3 North America Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.1.3.1 U.S.
• 3.1.3.2 Canada
• 3.2 Europe
• 3.2.1 Market Dynamics
• 3.2.2 Market Sizing and Forecast
• 3.2.3 Europe Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.2.3.1 U.K.
• 3.2.3.2 France
• 3.2.3.3 Germany
• 3.2.3.4 Italy
• 3.2.3.5 Spain
• 3.2.3.6 Rest-of-Europe
• 3.3 Asia-Pacific
• 3.3.1 Market Dynamics
• 3.3.2 Market Sizing and Forecast
• 3.3.3 Asia-Pacific Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.3.3.1 Japan
• 3.3.3.2 China
• 3.3.3.3 India
• 3.3.3.4 Australia
• 3.3.3.5 South Korea
• 3.3.3.6 Rest-of-Asia-Pacific
• 3.4 Rest-of-the-World
• 3.4.1 Market Dynamics
• 3.4.2 Market Sizing and Forecast Rest-of-the-World Corneal Ulcer Market, by Type ($Million), 2023-2035
• 3.4.3 Rest-of-the-World Corneal Ulcer Market, by Country ($Million), 2023-2035
• 3.4.3.1 Latin America
• 3.4.3.2 Middle East and Africa

4. Competitive Landscape and Company Profiles

• 4.1 Competitive Landscape
• 4.1.1 Mergers and Acquisitions
• 4.1.2 Partnership, Alliances and Business Expansion
• 4.1.3 New Offerings
• 4.1.4 Regulatory Activities
• 4.1.5 Funding Activities
• 4.2 Company Profiles
• 4.2.1 Overview
• 4.2.2 Top Products / Product Portfolio
• 4.2.3 Top Competitors
• 4.2.4 Target Customers/End-Users
• 4.2.5 Key Personnel
• 4.2.6 Analyst View

5. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/mlqff0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Dyslipidemia Market Research Report 2025-2035 | Expansion Fueled by Rising Cardiovascular Disease Burden, Lifestyle Risks, Early Diagnostics, and Preventive Health Initiatives – ResearchAndMarkets.com




Dyslipidemia Market Research Report 2025-2035 | Expansion Fueled by Rising Cardiovascular Disease Burden, Lifestyle Risks, Early Diagnostics, and Preventive Health Initiatives – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Dyslipidemia Market – A Global and Regional Analysis: Focus on Drug Class, Route of Administration, and Region – Analysis and Forecast, 2025-2035” report has been added to ResearchAndMarkets.com’s offering.

Dyslipidemia, characterized by abnormal levels of lipids such as cholesterol and triglycerides in the blood, significantly elevates the risk of cardiovascular diseases. Advances in lipid profiling, genetic testing, and risk assessment tools are enabling earlier and more precise diagnosis, thereby boosting demand for personalized therapeutic interventions. Statins remain the cornerstone of treatment, with newer drug classes such as PCSK9 inhibitors and RNA-based therapies gaining traction due to their efficacy in managing resistant cases.

However, challenges including patient non-compliance, side effects associated with long-term statin use, and high costs of novel therapies limit broader market penetration, especially in low and middle-income countries. Additionally, variations in treatment guidelines and healthcare infrastructure disparities complicate standardized care delivery. Nonetheless, growing government health initiatives, increased investment in cardiovascular research, and expanding awareness campaigns are driving improved screening and treatment rates.

Impact

Technological advancements in lipid diagnostics, genetic screening, and telemedicine platforms are significantly enhancing the early detection and personalized management of dyslipidemia. Innovations such as advanced lipid profiling, AI-driven risk prediction models, and wearable cardiovascular monitoring devices are improving the precision of disease assessment and treatment customization. Additionally, the integration of digital therapeutics and remote patient management is expanding access to care, particularly in underserved or rural areas, enabling continuous monitoring and better adherence to lipid-lowering therapies.

Statins hold the highest market share in the dyslipidemia market due to their proven efficacy, safety profile, and widespread clinical adoption as the first-line therapy for lowering LDL cholesterol and reducing cardiovascular risk. Extensive clinical trial evidence supports statins’ ability to significantly decrease morbidity and mortality associated with dyslipidemia-related conditions, which has solidified their position as the gold standard treatment globally.

Oral administration holds the highest market share in the dyslipidemia market, primarily because the majority of lipid-lowering drugs, including statins, fibrates, niacins, bile acid resins, and omega-3 fatty acids, are formulated for oral use. Oral medications offer greater patient convenience, ease of administration, and higher compliance compared to parenteral routes.

North America holds the highest market share in the dyslipidemia market, driven by its advanced healthcare infrastructure, high prevalence of cardiovascular diseases, and widespread adoption of lipid-lowering therapies. The region benefits from strong healthcare spending, well-established reimbursement frameworks, and early access to innovative treatments such as PCSK9 inhibitors.

How can this report add value to an organization?

Product/Innovation: This report provides comprehensive insights into the current trends in dyslipidemia, helping companies identify opportunities for drug and technology development. Organizations can leverage these insights to design therapies, medications, and platforms tailored to the needs of patients suffering from dyslipidemia, improving outcomes and enhancing market penetration.

Competitive: A detailed competitive landscape analysis helps organizations benchmark their market standing against key players. By understanding the strengths and weaknesses of competitors, companies can position themselves more effectively in the global dyslipidemia market.

Demand Drivers and Limitations

Drivers for the Global Dyslipidemia Market:

• Increasing cases of heart disease and stroke worldwide drive demand for effective lipid-lowering treatments.
• Lifestyle changes leading to obesity and diabetes contribute to higher dyslipidemia rates, boosting market growth
• Improved lipid profiling and genetic testing facilitate early diagnosis, increasing treatment uptake
• Public health initiatives promote regular cholesterol screening, leading to earlier intervention and therapy adoption

Limitations for the Global Dyslipidemia Market:

• Long-term medication adherence is often poor due to side effects and lack of symptom awareness, limiting treatment effectiveness
• Expensive drugs such as PCSK9 inhibitors restrict accessibility, especially in low- and middle-income countries.
• Adverse effects such as muscle pain and liver issues lead to discontinuation or reluctance in therapy initiation.

Key Market Players

• Amgen Inc.
• Sanofi S.A.
• Regeneron Pharmaceuticals, Inc.
• Pfizer Inc.
• Novartis AG
• Viatris Inc.
• AbbVie Inc.
• AstraZeneca plc
• Horizon Therapeutics plc
• Esperion Therapeutics, Inc.

Key Topics Covered:

1. Global Dyslipidemia Market: Industry Analysis

• 1.1 Market Overview and Ecosystem
• 1.2 Epidemiological Analysis
• 1.3 Key Market Trends
• 1.3.1 Impact Analysis
• 1.4 Regulatory Landscape
• 1.5 Pipeline Analysis
• 1.6 Market Dynamics
• 1.6.1 Overview
• 1.6.2 Market Drivers
• 1.6.3 Market Restraints
• 1.6.4 Market Opportunities

2. Global Dyslipidemia Market (by Drug Class), Value ($million), 2023-2035

• 2.1 Statins
• 2.2 Bile Acid Resins
• 2.3 Fibrates
• 2.4 Niacins
• 2.5 Omega-3 Fatty Acids
• 2.6 Others

3. Global Dyslipidemia Market (by Route of Administration), Value ($million), 2023-2035

• 3.1 Oral
• 3.2 Parenteral

4. Global Dyslipidemia Market (by Region), Value ($Million), 2023-2035

• 4.1 North America
• 4.1.1 Market Dynamics
• 4.1.2 Market Sizing and Forecast
• 4.1.3 North America Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.1.3.1 U.S.
• 4.1.3.2 Canada
• 4.2 Europe
• 4.2.1 Market Dynamics
• 4.2.2 Market Sizing and Forecast
• 4.2.3 Europe Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.2.3.1 U.K.
• 4.2.3.2 France
• 4.2.3.3 Germany
• 4.2.3.4 Italy
• 4.2.3.5 Spain
• 4.2.3.6 Rest-of-Europe
• 4.3 Asia-Pacific
• 4.3.1 Market Dynamics
• 4.3.2 Market Sizing and Forecast
• 4.3.3 Asia-Pacific Dyslipidemia Market, by Country ($Million), 2023-2035
• 4.3.3.1 Japan
• 4.3.3.2 China
• 4.3.3.3 India
• 4.3.3.4 Australia
• 4.3.3.5 South Korea
• 4.3.3.6 Rest-of-Asia-Pacific
• 4.4 Rest-of-the-World
• 4.4.1 Market Dynamics
• 4.4.2 Market Sizing and Forecast Rest-of-the-World Dyslipidemia Market, by Type ($Million), 2023-2035
• 4.4.3 Rest-of-the-World Dyslipidemia Disorder Market, by Country ($Million), 2023-2035
• 4.4.3.1 Latin America
• 4.4.3.2 Middle East and Africa

5. Competitive Landscape and Company Profiles

• 5.1 Competitive Landscape
• 5.1.1 Mergers and Acquisitions
• 5.1.2 Partnership, Alliances and Business Expansion
• 5.1.3 New Offerings
• 5.1.4 Regulatory Activities
• 5.1.5 Funding Activities
• 5.2 Company Profiles
• 5.2.1 Overview
• 5.2.2 Top Products / Product Portfolio
• 5.2.3 Top Competitors
• 5.2.4 Target Customers/End-Users
• 5.2.5 Key Personnel
• 5.2.6 Analyst View

6. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/htp9qf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900